"VTYX Stock Plummets as Psoriasis Treatment Trials Fail"

Biotech company Ventyx Biosciences saw its stock plummet by over 80% after its psoriasis drug, VTX958, failed to meet efficacy expectations in Phase 2 testing. Only two out of four doses showed statistically significant improvements in symptoms, leading the company to abandon further development in the highly competitive psoriasis market. Ventyx is terminating the psoriasis study and an ongoing test in psoriatic arthritis but will continue studying VTX958 in patients with Crohn's disease.